Timothy A Chan

List of Publications by Year
in descending order

172 papers	45,580 citations	8755 75 h-index	5829 161 g-index
183 all docs	183 docs citations	183 times ranked	49953 citing authors

#	Article	IF	Citations
1	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	12.6	6,756
2	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2189-2199.	27.0	3,753
3	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
4	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	27.0	2,582
5	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	12.6	2,445
6	IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 2012, 483, 474-478.	27.8	1,693
7	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012, 483, 479-483.	27.8	1,668
8	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews Cancer, 2019, 19, 133-150.	28.4	1,657
9	CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature, 2019, 569, 270-274.	27.8	1,528
10	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017, 171, 934-949.e16.	28.9	1,515
11	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell, 2015, 162, 974-986.	28.9	1,408
12	An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science, 2013, 340, 626-630.	12.6	1,014
13	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	27.8	854
14	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 359, 582-587.	12.6	834
15	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 2016, 17, 231.	8.8	746
16	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
17	The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight, 2016, 1, e89829.	5.0	569
18	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017, 551, 517-520.	27.8	532

#	Article	IF	Citations
19	The hallmarks of successful anticancer immunotherapy. Science Translational Medicine, 2018, 10, .	12.4	419
20	Genetic diversity of tumors with mismatch repair deficiency influences antiâ€“PD-1 immunotherapy response. Science, 2019, 364, 485-491.	12.6	395
21	The mutational landscape of adenoid cystic carcinoma. Nature Genetics, 2013, 45, 791-798.	21.4	394
22	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nature Medicine, 2013, 19, 901-908.	30.7	388
23	Stereotactic Radiosurgery for Melanoma BrainÂMetastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. International Journal of Radiation Oncology Biology Physics, 2015, 92, 368-375.	0.8	334
24	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget, 2016, 7, 3403-3415.	1.8	306
25	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature Medicine, 2019, 25, 767-775.	30.7	282
26	Corticosteroids compromise survival in glioblastoma. Brain, 2016, 139, 1458-1471.	7.6	271
27	Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nature Genetics, 2016, 48, 59-66.	21.4	253
28	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget, 2016, 7, 10051-10063.	1.8	247
29	Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules. Cell, 2014, 156, 603-616.	28.9	241
30	Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget, 2012, 3, 1194-1203.	1.8	241
31	Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. Journal of Neuro-Oncology, 2015, 125, 149-156.	2.9	224
32	NF-Î°B c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. Cell, 2017, 170, 1096-1108.e13.	28.9	222
33	A Phase 2 Trial of Stereotactic Radiosurgery Boost After Surgical Resection for Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2014, 88, 130-136.	0.8	218
34	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013, 4, 1729-1736.	1.8	213
35	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 729.	12.8	212
36	Integrated Genomic Analysis of HÃ¼rthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell, 2018, 34, 256-270.e5.	16.8	195

#	Article	IF	Citations
37	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nature Medicine, 2019, 25, 1715-1720.	30.7	194
38	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	7.1	191
39	Cancer Neoantigens and Applications for Immunotherapy. Clinical Cancer Research, 2016, 22, 807-812.	7.0	188
40	Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. Cancer Cell, 2021, 39, 662-677.e6.	16.8	179
41	Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discovery, 2019, 9, 510-525.	9.4	169
42	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research, 2016, 22, 4623-4633.	7.0	153
43	Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. Trends in Immunology, 2018, 39, 536-548.	6.8	152
44	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genetics, 2014, 46, 588-594.	21.4	144
45	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clinical Cancer Research, 2017, 23, 4429-4440.	7.0	142
46	HIF-1Î± and HIF-2Î± differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nature Communications, 2020, 11, 4111.	12.8	141
47	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget, 2013, 4, 1737-1747.	1.8	141
48	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	21.4	139
49	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLoS Biology, 2020, 18, e3000970.	5.6	139
50	ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nature Communications, 2018, 9, 4158.	12.8	138
51	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. Journal of the National Cancer Institute, 2018, 110, 1386-1392.	6.3	137
52	TGF-Î² suppresses type 2 immunity to cancer. Nature, 2020, 587, 115-120.	27.8	137
53	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nature Genetics, 2018, 50, 62-72.	21.4	137
54	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. Journal of Clinical Investigation, 2019, 129, 4276-4289.	8.2	134

#	Article	IF	Citations
55	Genomic landscape of adenoid cystic carcinoma of the breast. Journal of Pathology, 2015, 237, 179-189.	4.5	133
56	G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nature Communications, 2019, 10, 943.	12.8	132
57	IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma. Clinical Cancer Research, 2012, 18, 2490-2501.	7.0	127
58	Response Rates to Antiâ€“PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncology, 2021, 7, 739.	7.1	125
59	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncology, The, 2020, 21, 283-293.	10.7	121
60	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Lancet Oncology, The, 2018, 19, 1688-1698.	10.7	119
61	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nature Genetics, 2016, 48, 1327-1329.	21.4	115
62	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer, 2020, 1, 1188-1203.	13.2	114
63	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation, 2020, 130, 2712-2726.	8.2	112
64	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	17.5	110
65	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	7.0	107
66	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research, 2016, 76, 6495-6506.	0.9	105
67	FAT1 mutations cause a glomerulotubular nephropathy. Nature Communications, 2016, 7, 10822.	12.8	99
68	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. Journal of the National Cancer Institute, 2021, 113, 742-751.	6.3	98
69	An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. Cell Reports, 2017, 20, 1623-1640.	6.4	96
70	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. , 2017, 5, 76.		96
71	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clinical Cancer Research, 2016, 22, 4786-4796.	7.0	95
72	Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight, 2020, 5, .	5.0	95

#	Article	IF	Citations
73	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discovery, 2016, 6, 703-713.	9.4	92
74	Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 322-329.	0.8	91
75	Antitumour immunity gets a boost. Nature, 2014, 515, 496-498.	27.8	90
76	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2014, 20, 5023-5031.	7.0	89
77	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clinical Cancer Research, 2017, 23, 5970-5980.	7.0	89
78	RIG-I activation is critical for responsiveness to checkpoint blockade. Science Immunology, 2019, 4, .	11.9	80
79	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes and Diseases, 2014, 1, 75-86.	3.4	78
80	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nature Communications, 2017, 8, 1197.	12.8	77
81	Sarcomatoid renal cell carcinoma: biology, natural history and management. Nature Reviews Urology, 2020, 17, 659-678.	3.8	76
82	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. Clinical Cancer Research, 2020, 26, 2859-2870.	7.0	75
83	Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology, 2014, 16, 1186-1195.	1.2	69
84	Transcriptional Mechanisms of Resistance to Antiâ€“PD-1 Therapy. Clinical Cancer Research, 2017, 23, 3168-3180.	7.0	67
85	Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Science Advances, 2020, 6, eaaz3221.	10.3	67
86	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications, 2018, 9, 1057.	12.8	66
87	Immunogenic peptide discovery in cancer genomes. Current Opinion in Genetics and Development, 2015, 30, 7-16.	3.3	63
88	Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. Clinical Cancer Research, 2018, 24, 963-971.	7.0	57
89	Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. PLoS ONE, 2015, 10, e0135750.	2.5	51
90	Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. Cancer Cell, 2016, 29, 737-750.	16.8	50

#	Article	IF	Citations
91	Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro-Oncology, 2019, 21, 189-200.	1.2	49
92	The status of tumor mutational burden and immunotherapy. Nature Cancer, 2022, 3, 652-656.	13.2	48
93	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Human Vaccines and Immunotherapeutics, 2020, 16, 112-115.	3.3	47
94	APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. Oral Oncology, 2019, 96, 140-147.	1.5	46
95	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications, 2020, 11, 4168.	12.8	46
96	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers, 2020, 12, 1221.	3.7	46
97	Remodeling of the Methylation Landscape in Breast Cancer Metastasis. PLoS ONE, 2014, 9, e103896.	2.5	43
98	ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis. Cancer Immunology Research, 2018, 6, 151-162.	3.4	42
99	Genetic and environmental determinants of human TCR repertoire diversity. Immunity and Ageing, 2020, 17, 26.	4.2	42
100	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 797-804.	0.8	40
101	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of Clinical Oncology, 2018, 36, 1702-1709.	1.6	39
102	Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies. Nature Immunology, 2022, 23, 904-915.	14.5	39
103	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	6.3	38
104	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
105	Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). Pharmaceuticals, 2021, 14, 447.	3.8	32
106	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Molecular and Cellular Oncology, 2016, 3, e1048929.	0.7	31
107	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM. Oncotarget, 2017, 8, 10312-10323.	1.8	31
108	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	7.0	30

#	Article	IF	Citations
109	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nature Genetics, 2022, 54, 996-1012.	21.4	30
110	Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity. JAMA Network Open, 2021, 4, e217746.	5.9	29
111	Outcomes and Prognostic Factors in Women With 1 to 3 Breast Cancer Brain Metastases Treated With Definitive Stereotactic Radiosurgery. International Journal of Radiation Oncology Biology Physics, 2014, 90, 518-525.	0.8	28
112	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer, 2018, 18, 225.	2.6	28
113	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus, 2021, 7, 381-389.	3.1	28
114	Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biology and Therapy, 2014, 15, 623-632.	3.4	27
115	Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. Neoplasia, 2017, 19, 75-83.	5.3	27
116	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. Blood, 2021, 138, 2781-2798.	1.4	27
117	Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. Clinical Cancer Research, 2019, 25, 1226-1232.	7.0	26
118	Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade. JAMA Network Open, 2022, 5, e220448.	5.9	26
119	CD97 is a critical regulator of acute myeloid leukemia stem cell function. Journal of Experimental Medicine, 2019, 216, 2362-2377.	8.5	24
120	Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. Clinical Cancer Research, 2017, 23, 3109-3119.	7.0	23
121	Regularized quantile regression under heterogeneous sparsity with application to quantitative genetic traits. Computational Statistics and Data Analysis, 2016, 95, 222-239.	1.2	22
122	Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. Oral Oncology, 2020, 110, 104877.	1.5	22
123	Deletion ofPtprdandCdkn2acooperate to accelerate tumorigenesis. Oncotarget, 2014, 5, 6976-6982.	1.8	22
124	H3K9 methylation drives resistance to androgen receptorâ€“antagonist therapy in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2114324119.	7.1	21
125	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. Molecular Cancer Research, 2021, 19, 1510-1521.	3.4	20
126	Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types. Cancer Research, 2022, 82, 2076-2083.	0.9	18

#	Article	IF	Citations
127	Immunotherapy and Oncogenic Pathways: The PTEN Connection. Cancer Discovery, 2016, 6, 128-129.	9.4	17
128	Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade. Npj Precision Oncology, 2022, 6, 23.	5.4	17
129	Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5 Ã— 6 Gy) conformal radiotherapy. Radiotherapy and Oncology, 2017, 123, 203-208.	0.6	16
130	The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy. Genome Medicine, 2019, 11, 43.	8.2	16
131	Diverse Neoantigens and the Development of Cancer Therapies. Seminars in Radiation Oncology, 2020, 30, 113-128.	2.2	15
132	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications, 2021, 12, 6821.	12.8	15
133	Mitonuclear genotype remodels the metabolic and microenvironmental landscape of HÃ¼rthle cell carcinoma. Science Advances, 2022, 8, .	10.3	15
134	Immunotherapy biomarkers: the long and winding road. Nature Reviews Clinical Oncology, 2021, 18, 323-324.	27.6	14
135	PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. Oncotarget, 2017, 8, 15827-15837.	1.8	14
136	Multimodal single-cell omics analysis identifies epitheliumâ€“immune cell interactions and immune vulnerability associated with sex differences in COVID-19. Signal Transduction and Targeted Therapy, 2021, 6, 292.	17.1	13
137	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. Molecular Cancer Research, 2022, 20, 45-55.	3.4	13
138	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 5595-5606.	7.0	12
139	Qa-1b Modulates Resistance to Antiâ€“PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. Molecular Cancer Research, 2021, 19, 1076-1084.	3.4	11
140	My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype. Genome Biology, 2021, 22, 53.	8.8	11
141	Agingâ€related cell typeâ€specific pathophysiologic immune responses that exacerbate disease severity in aged COVIDâ€19 patients. Aging Cell, 2022, 21, e13544.	6.7	11
142	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science Translational Medicine, 2022, 14, .	12.4	10
143	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. Journal of Clinical Investigation, 2022, 132, .	8.2	9
144	Survival of patients treated with radiation therapy for anaplastic astrocytoma. Radiology and Oncology, 2014, 48, 381-386.	1.7	8

#	Article	IF	Citations
145	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. Oncotarget, 2019, 10, 3835-3839.	1.8	8
146	Precision regenerative medicine. Stem Cell Research and Therapy, 2021, 12, 39.	5.5	8
147	Ectopic activation of the miR-200câ€“EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. Science Translational Medicine, 2021, 13, eabg4328.	12.4	8
148	Genetics and immunology: reinvigorated. OncoImmunology, 2015, 4, e1029705.	4.6	7
149	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2022, 12, 2308-2329.	9.4	7
150	Lung Cancer Evolution: Whatâ€™s Immunity Got to Do with It?. Cancer Cell, 2019, 35, 711-713.	16.8	6
151	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. Clinical Cancer Research, 2021, 27, 1516-1525.	7.0	6
152	Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. Molecular Cancer Therapeutics, 2022, 21, 382-394.	4.1	6
153	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. Neoplasia, 2022, 28, 100790.	5.3	5
154	Dissecting microsatellite instability in colorectal cancer: one size does not fit all. Genome Medicine, 2017, 9, 45.	8.2	4
155	High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. Journal of Neuro-Oncology, 2019, 142, 523-528.	2.9	4
156	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. Human Molecular Genetics, 2020, 29, R214-R225.	2.9	3
157	CD97 Is a Critical Regulator of Acute Myeloid Leukemia Stem Cell Function. Blood, 2016, 128, 1077-1077.	1.4	3
158	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. American Journal of Cancer Research, 2021, 11, 3628-3644.	1.4	3
159	Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation. International Journal of Radiation Oncology Biology Physics, 2018, 101, 833-844.	0.8	1
160	Resource-efficient pooled sequencing expands translational impact in solid tumors. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 18-23.	0.1	1
161	RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade. Blood, 2019, 134, 624-624.	1.4	1
162	ATPS-44INHIBITION OF POLO-LIKE KINASE 1 SENSITIZESISOCITRATE DEHYDROGENASE 1MUTANT ASTROCYTES TO TEMOZOLOMIDE TREATMENT. Neuro-Oncology, 2015, 17, v27.5-v28.	1.2	0

#	Article	IF	Citations
163	Pursuing Immunotherapeutic Targets in SCLC. Journal of Thoracic Oncology, 2021, 16, 1056-1057.	1.1	0
164	Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarkerâ€"Reply. JAMA Oncology, 2021, 7, 1245.	7.1	0
165	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 2-3.	1.4	0
166	Title is missing!. , 2020, 18, e3000970.		0
167	Title is missing!. , 2020, 18, e3000970.		0
168	Title is missing!. , 2020, 18, e3000970.		0
169	Title is missing!. , 2020, 18, e3000970.		0
170	Title is missing!. , 2020, 18, e3000970.		0
171	Title is missing!. , 2020, 18, e3000970.		0
172	Title is missing!. , 2020, 18, e3000970.		0